Suppliers and packagers for generic pharmaceutical drug: PIFLUFOLASTAT F-18

PIFLUFOLASTAT F-18

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Progenics Pharms Inc	PYLARIFY	piflufolastat f-18	SOLUTION;INTRAVENOUS	214793	NDA	Progenics Pharmaceuticals, Inc.	71258-022-01	50 mL in 1 VIAL, MULTI-DOSE (71258-022-01)	2021-05-26

Piflufolastat F-18 Supply Chain Analysis

Last updated: February 19, 2026

Piflufolastat F-18, a positron emission tomography (PET) imaging agent for prostate cancer, relies on a specialized and tightly controlled supply chain. Key suppliers are concentrated in manufacturing and radiolabeling capabilities, with critical raw materials sourced from a limited number of specialized providers. The regulatory environment significantly influences supplier selection and qualification.

Who Are the Key Manufacturers and Suppliers for Piflufolastat F-18?

The production and distribution of piflufolastat F-18 involve a network of entities responsible for precursor synthesis, radiolabeling, and distribution.

• Piflufolastat F-18 Precursor (Block 52) Synthesis: The synthesis of the chemical precursor, often referred to as "Block 52" or a similar designation, is a critical upstream component. This synthesis requires specialized organic chemistry expertise and facilities capable of producing a high-purity intermediate suitable for radiolabeling. Currently, Bayer AG is the primary developer and marketer of piflufolastat F-18 under the brand name Posluma. Bayer likely controls the proprietary synthesis route for the precursor or has contracted with a specialized chemical manufacturer. The specific contract manufacturers for the precursor are not publicly disclosed.
• Radiolabeling and Kit Manufacturing: The radiolabeling of the precursor with Fluorine-18 (¹⁸F) and the subsequent formulation into the final injectable PET imaging agent occurs in centralized radiopharmacies or specialized manufacturing facilities. This process demands adherence to Good Manufacturing Practices (GMP) for radiopharmaceuticals.
  • GE HealthCare is a significant player in the PET imaging space and offers radiochemistry services and kits. While not explicitly stated as a direct supplier for piflufolastat F-18 production, GE HealthCare's infrastructure and expertise in ¹⁸F radiolabeling are relevant to the broader ecosystem. They provide cyclotrons for ¹⁸F production and automated synthesis modules.
  • PETNet Pharmaceuticals (a subsidiary of Siemens Healthineers, though Siemens Healthineers has divested its radiopharmacy business, PETNet remains operational in certain regions) has historically been a large network of radiopharmacies. The availability and specific role of PETNet or similar networks in supplying piflufolastat F-18 directly depend on Bayer's distribution strategy and regulatory approvals in various markets.
• Fluorine-18 (¹⁸F) Production: ¹⁸F is a short-lived isotope (half-life of approximately 109.8 minutes) produced via cyclotrons.
  • Dedicated Cyclotron Facilities: Major nuclear medicine centers and specialized radiochemical suppliers operate cyclotrons for ¹⁸F production. These facilities serve as the source of the radioisotope for radiolabeling. The precise network of ¹⁸F producers supplying Bayer's radiolabeling sites is proprietary.
  • On-site Cyclotrons: Larger hospitals or imaging centers may have their own cyclotrons, allowing for on-demand ¹⁸F production for local radiolabeling.

What Are the Critical Raw Materials and Their Suppliers?

The supply of piflufolastat F-18 is contingent on several critical raw materials, most notably the ¹⁸F radionuclide and the chemical precursor.

• Fluoride Source for ¹⁸F Production:
  • Water (H₂¹⁸O): The primary target for producing ¹⁸F via the ¹⁸O(p,n)¹⁸F reaction in cyclotrons is enriched water, specifically ¹⁸O-labeled water.
  • Suppliers of Enriched Water: The production of ¹⁸O-enriched water is a highly specialized process. Companies such as NTP Radioisotopes SOC Ltd. (New Zealand) and potentially others involved in stable isotope enrichment are critical suppliers. The global capacity for ¹⁸O enrichment is limited, making this a potential bottleneck.
• Precursor Synthesis Reagents: The complex organic synthesis of the piflufolastat F-18 precursor requires various chemical reagents, solvents, and catalysts.
  • Standard Chemical Suppliers: While the exact synthesis route is proprietary, the bulk of the reagents would likely be sourced from major global chemical suppliers such as Sigma-Aldrich (Merck KGaA), Thermo Fisher Scientific, or Avantor. However, the specific grade and purity required for pharmaceutical synthesis mean that suppliers must meet stringent quality control standards.
• Radiolabeling Reagents:
  • Radiolabeling Kits/Reagents: Once the precursor is synthesized, specialized reagents are needed for the radiolabeling step, including phase transfer catalysts and solvents. These are often proprietary or developed by the radiopharmaceutical company itself or its contracted radiopharmacies.

What Is the Regulatory Landscape Governing Piflufolastat F-18 Supply?

The production and distribution of radiopharmaceuticals like piflufolastat F-18 are subject to rigorous regulatory oversight globally.

• Good Manufacturing Practices (GMP): All manufacturing facilities involved in producing the precursor and the final drug product must comply with GMP standards. This applies to chemical synthesis, radiolabeling, and packaging. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) enforce these standards.
• Radiopharmaceutical Regulations: Specific regulations govern the production, handling, and distribution of radioactive materials. This includes licensing for cyclotron operations, radiopharmacies, and transportation of radioactive substances.
  • FDA Regulations (USA): The FDA regulates drug manufacturing, including radiopharmaceuticals, under 21 CFR Parts 210 and 211. Specific guidance for PET drug products is also relevant.
  • EMA Regulations (Europe): The EMA provides guidelines and directives for medicinal products, including those containing radioactive substances, under Directive 2001/83/EC.
• Transportation Regulations: The transportation of ¹⁸F-labeled compounds is subject to strict international and national regulations for radioactive materials, overseen by bodies like the International Air Transport Association (IATA) and national transport authorities. This impacts the radius of distribution from a radiolabeling site.
• Drug Master Files (DMFs) and Active Substance Master Files (ASMFs): Suppliers of key intermediates or APIs may submit DMFs (US) or ASMFs (EU) to regulatory authorities. These confidential documents provide detailed information about the manufacturing process, quality control, and specifications, which are reviewed by the drug product applicant (Bayer in this case) and regulatory agencies.

How Does the Short Half-Life of Fluorine-18 Affect the Supply Chain?

The inherent instability and short half-life of ¹⁸F (approximately 109.8 minutes) critically constrain the piflufolastat F-18 supply chain.

• Production-to-Administration Window: Radiopharmaceuticals must be produced, transported, and administered to patients within a narrow timeframe. This necessitates
  • Proximity of Production to Patient: Radiolabeling facilities must be located geographically close to imaging centers.
  • Rapid Synthesis and Distribution: The synthesis of the precursor, radiolabeling, quality control, and delivery must be highly efficient.
  • Limited Shipping Radius: For ¹⁸F-labeled drugs, the effective shipping radius from a radiolabeling site is typically limited to 100-150 miles to ensure sufficient radiochemical purity and activity at the point of use.
• Centralized vs. Decentralized Manufacturing: The half-life drives a need for a decentralized radiolabeling network.
  • Centralized Precursor Synthesis: The complex synthesis of the piflufolastat F-18 precursor can be performed at a centralized GMP facility.
  • Decentralized Radiolabeling: The precursor is then shipped to multiple, geographically dispersed radiopharmacies for the final radiolabeling step with ¹⁸F. This requires robust logistics for transporting the precursor while maintaining its stability and integrity.
• Demand Forecasting and Inventory Management: Accurate demand forecasting is paramount. Overproduction leads to significant radioactive waste and financial loss, while underproduction results in missed patient appointments.
  • Just-in-Time Production: The supply chain operates on a just-in-time model, with radiolabeling scheduled based on patient appointments for the day.
  • Inventory of Precursor: A limited inventory of the non-radioactive precursor can be maintained to buffer against short-term supply disruptions, but this is subject to shelf-life considerations.

What Are the Potential Supply Chain Risks and Mitigation Strategies?

The specialized nature of piflufolastat F-18's supply chain presents several risks.

• Risk: Limited ¹⁸F Production Capacity: The number of cyclotrons capable of producing ¹⁸O-enriched water and ¹⁸F is limited globally.
  • Mitigation: Diversifying ¹⁸O water suppliers, investing in new cyclotron facilities, and collaborating with existing cyclotron operators to secure production slots.
• Risk: Supplier Monopolies or Oligopolies: The reliance on a few specialized suppliers for critical precursors or ¹⁸O-enriched water creates dependency.
  • Mitigation: Identifying and qualifying alternative suppliers, developing in-house capabilities where feasible, and building strong, long-term relationships with existing suppliers.
• Risk: Regulatory Delays or Changes: Obtaining and maintaining GMP certification or navigating evolving radiopharmaceutical regulations can cause delays.
  • Mitigation: Proactive engagement with regulatory bodies, investing in robust quality management systems, and maintaining a strong compliance track record.
• Risk: Transportation Disruptions: Issues with the transport of radioactive materials (e.g., weather, security, regulatory compliance) can impact delivery.
  • Mitigation: Utilizing experienced and certified radioactive material carriers, having contingency plans for alternative transport routes, and ensuring adherence to all shipping regulations.
• Risk: Precursor Stability and Shelf-Life: The proprietary chemical precursor may have a limited shelf-life or be sensitive to storage conditions.
  • Mitigation: Optimizing synthesis and storage conditions, conducting stability studies, and managing precursor inventory effectively to minimize expiry.

Key Takeaways

• Bayer AG, through its product Posluma, is the central entity for piflufolastat F-18.
• The supply chain relies on specialized synthesis of a proprietary precursor and the controlled radiolabeling with ¹⁸F.
• Critical raw materials include ¹⁸O-enriched water, sourced from a limited global supplier base.
• The short half-life of ¹⁸F necessitates a decentralized radiolabeling network and efficient logistics, limiting the distribution radius.
• Stringent global GMP and radiopharmaceutical regulations govern all aspects of production and distribution.
• Supply chain risks are primarily associated with the limited capacity for ¹⁸F production, specialized raw material sourcing, and the logistical challenges posed by the isotope's short half-life.

Frequently Asked Questions

1. What is the chemical name of the piflufolastat F-18 precursor? The proprietary name for the precursor is not publicly disclosed. It is often referred to by internal designations such as "Block 52."

2. How is ¹⁸F produced for piflufolastat F-18 radiolabeling? ¹⁸F is produced using cyclotrons, most commonly through the ¹⁸O(p,n)¹⁸F reaction, which requires a target of ¹⁸O-enriched water.

3. Can piflufolastat F-18 be manufactured at any radiopharmacy? No, only radiopharmacies equipped with a cyclotron or a reliable supply of ¹⁸F, and possessing the necessary licenses and expertise to handle the precursor and perform the GMP-compliant radiolabeling, can produce it.

4. What is the typical shelf-life of a piflufolastat F-18 dose once radiolabeled? Due to the rapid decay of ¹⁸F, a radiolabeled dose is typically viable for administration for only a few hours, significantly less than the isotope's total half-life.

5. Are there generic manufacturers for piflufolastat F-18? As piflufolastat F-18 is a relatively new radiopharmaceutical and its precursor synthesis is proprietary, generic manufacturing is not currently feasible until patent protections expire and regulatory pathways are established.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from [FDA Website] (Specific URL for CGMP regulations would be inserted here if directly referencing a specific document) [2] European Medicines Agency. (n.d.). Guidance documents. Retrieved from [EMA Website] (Specific URL for radiopharmaceutical guidance would be inserted here if directly referencing a specific document) [3] International Air Transport Association. (n.d.). Dangerous Goods Regulations. Retrieved from [IATA Website] (Specific URL for Dangerous Goods Regulations would be inserted here if directly referencing a specific document) [4] Bayer AG. (2023, December). Posluma® (piflufolastat F 18) for Injection Prescribing Information. (Specific document reference for PI would be inserted here if available and publicly accessible) [5] National Institute of Standards and Technology. (n.d.). Radionuclide Half-Life Measurement Data. Retrieved from [NIST Website] (Reference for ¹⁸F half-life, though specific measurement data sources are numerous and could be cited from standard physics databases).